Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL11876258 | 0.92 | ALDH1A1 (0.46) | ALDH1A1LMNA | |
| Ether SCHEMBL8431870 | 0.91 | ALDH1A1 (0.36) | ALDH1A1TSHRLMNA | |
| Ether SCHEMBL437946 | 0.91 | LMNA (0.37) | ALDH1A1LMNA | |
| Ether SCHEMBL9793363 | 0.91 | LMNA (0.37) | ALDH1A1LMNA | |
| Ether SCHEMBL5404357 | 0.88 | TSHR (0.36) | ALDH1A1TSHRLMNA | |
| Alcohol SCHEMBL168419 | 0.87 | TSHR (0.46) | ALDH1A1TSHRLMNA | |
| Alcohol SCHEMBL18544095 | 0.87 | TSHR (0.46) | ALDH1A1TSHRLMNA | |
| Alcohol SCHEMBL2888838 | 0.84 | TSHR (0.43) | ALDH1A1TSHRLMNA | |
| Ether SCHEMBL15135184 | 0.82 | MAPK1 (0.36) | LMNA | |
| Isopropyl Alcohol SCHEMBL6672907 | 0.81 | TSHR (0.40) | ALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115139-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-2481725-B1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-03-04 | — | — | EP | disclosed |
| CN-102458579-B | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL | 2014-11-05 | — | — | CN | disclosed |
| US-8815920-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-08-26 | — | — | US | disclosed |
| EP-2442870-B1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8669246-B2 | Substituted amide compound | ASTELLAS PHARMA INC. (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-09-05 | — | — | US | disclosed |
| US-8324201-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-8318722-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8314088-B2 | Pyrazinooxazepine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-20 | — | — | US | disclosed |
| EP-2481725-A1 | SUBSTITUTED AMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-31 | — | — | US | disclosed |
| CN-102458579-A | Pyrazinoazeza derivatives | TAKEDA PHARMACEUTICAL | 2012-05-16 | — | — | CN | disclosed |
| EP-2442870-A1 | PYRAZINOOXAZEPINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-24 | — | — | US | disclosed |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | SASAKI SHIGEKAZU (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2010147226-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135979-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR5A, HTR2C, HTR2A | ALDH1A1 1312/4885TSHR 1403/4885LMNA 3144/4885 |
| US-20100317651-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | ALDH1A1 2564/4885TSHR 362/4885LMNA 2982/4885 |
| US-20120184521-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | ALDH1A1 3512/4885TSHR 525/4885LMNA 555/4885 |
| US-20110288291-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | ALDH1A1 2564/4885TSHR 362/4885LMNA 2982/4885 |
| US-20130231320-A1 | SUBSTITUTED AMIDE COMPOUND | LPAR1, LPAR2, LPAR3 | ALDH1A1 3520/4885TSHR 519/4885LMNA 557/4885 |
| US-20110282054-A1 | PYRAZINOOXAZEPINE DERIVATIVES | HTR2C, HTR5A, HTR2A | ALDH1A1 2564/4885TSHR 362/4885LMNA 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.